Diana Bonderman, ESC 2021 – the DYNAMIC Study
Prof. Diana Bonderman (Cardiologist, Medical University of Vienna, Vienna, Austria) kindly shared her thoughts on the current challenges in the treatment of pulmonary hypertension and heart failure with preserved ejection fraction, the mechanism and use of riociguat, and the DYNAMIC study (NCT02744339) from from the virtual ESC Congress 2021.
- What are the challenges in the treatment of pulmonary hypertension and heart failure with preserved ejection fraction (HFpEF)? (0.26)
- What is the mechanism of action of riociguat, and what clinical evidence supports its use in pulmonary hypertension associated with HFpEF? (1.39)
- What were the aims, design and eligibility criteria of the DYNAMIC study? (2.33)
- What were the efficacy and safety findings of the study? (3.38)
- What were the investigator’s conclusions and what further studies are planned? (4.08)
Speaker disclosures: Prof. Diana Bronderman has received speaker honoraria and research grants from Bayer, MSD, Pfizer, Janssen, Ionis, Alnylam, Zoll, Novartis, Boehringer Ingelheim and AstraZeneca.
Support: Interview and filming supported by Touch Medical Media and conducted by Heather Hall.
Filmed during a remote video call with Professor Diana Bonderman as a highlight of ESC 2021, August 2021.
Share this Video
Related Videos In Hypertension
Kelly Chin, ACC 2023: The treatment paradigm for patients with pulmonary arterial hypertension
Recommended therapy for patients with pulmonary arterial hypertension is generally a combination of an endothelin receptor antagonist and a phosphodiesterase type 5 inhibitor. In this touchCARDIO interview, we speak with Dr Kelly Chin (UT Southwestern Medical Centre, Dallas, TX, USA) to discuss the treatment paradigm. Dr Chin presented an abstract entitled ‘Efficacy And Safety Of […]
Kelly Chin, ACC 2023: A DUE phase III study, a macitentan and tadalafil combination for patients with pulmonary arterial hypertension
The aim of the A DUE study was to assess the combination of macitentan and tadalafil for patients with pulmonary arterial hypertension. In this touchCARDIO interview, we speak with Dr Kelly Chin (UT Southwestern Medical Centre, Dallas, TX, USA) to discuss the findings of the trial and the clinical impact. The abstract entitled ‘Efficacy And […]
Marius Hoeper, ACC 2023: STELLAR phase III trial results – Sotatercept for the treatment of pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a progressive disease involving proliferative remodeling of the pulmonary vessels and elevations in pulmonary vascular resistance (PVR). Despite recent treatment advances, the associated morbidity and mortality rates of the disease are still high. In this touchCARDIO interview, we speak with Prof. Marius Hoeper (Department of Respiratory Medicine, Hannover Medical School, Hannover, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!